DexCom, Inc.
DexCom, Inc.
Your view on DXCM
Overview
What the company does, where it operates, and who runs it.
About DexCom, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Jacob Steven Leach
- Headquarters
- 6340 Sequence Drive, San Diego, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Jacob Steven Leach
- Headquarters
- 6340 Sequence Drive, San Diego, CA, US
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.
Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.
The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for DexCom, Inc. from FRC's valuation model, read against the market price. DXCM last traded at $81.61, 31.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for DexCom, Inc.. Starting points for DexCom, Inc.: P/E 31.6, EPS $2.64, beta 1.44 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for DexCom, Inc.. DexCom, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for DexCom, Inc.. Trailing twelve-month EPS for DexCom, Inc. stands at $2.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$94.75
average of 16 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy19
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.72 | $0.63 | $2.70 | $3.14 |
| Low estimate | $0.68 | $0.58 | $2.47 | $2.82 |
| High estimate | $0.77 | $0.67 | $2.77 | $3.28 |
| No. of analysts | 15 | 11 | 15 | 16 |
| Year-ago EPS | $0.68 | $0.56 | $2.09 | — |
| Growth | +5.2% | +13.1% | +29.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.38B | $1.31B | $5.23B | $5.77B |
| Low estimate | $1.37B | $1.30B | $5.21B | $5.68B |
| High estimate | $1.39B | $1.32B | $5.25B | $5.87B |
| No. of analysts | 16 | 11 | 21 | 21 |
| Year-ago revenue | $1.26B | $1.19B | $4.66B | — |
| Growth | +9.9% | +10.1% | +12.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for DexCom, Inc.. DexCom, Inc. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- BBNXBeta Bionics, Inc.Medical - Devices$684M
- DRIODarioHealth Corp.Medical - Specialties$11M
- GCTKGlucoTrack, Inc.Medical - Devices$179,582
- MMEDMiniMed Group, Inc. Common StockMedical - Equipment & Services$5.2B
- PODDInsulet CorporationMedical - Devices$10.1B
- SENSSenseonics Holdings, Inc.Medical - Devices$597M
More Medical - Devices companies
- LPTILongport, Inc.OTC$2,308
- LUCDLucid Diagnostics Inc.NASDAQ$77M
- LUDGLudwig Enterprises, Inc.OTC$4M
- LUNGPulmonx CorporationNASDAQ$122M
- MBOTMicrobot Medical Inc.NASDAQ$43M
- MCRPFMicroPort Scientific CorporationOTC$2.9B
- MDRSFMedartis Holding AGOTC$1.2B
- MDTMedtronic plcNYSE$131.6B
- MDXHFMedX Health CorpOTC$7M
- MHTXManhattan Scientifics, Inc.OTC$55,928
- MICRMicron Solutions, Inc.OTC$634
- MMTCMicro Imaging Technology, Inc.OTC$901
ETFs holding DexCom, Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.05%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.04%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets0.15%
- VOVanguard Mid-Cap ETF$103.4B in assets0.30%
- SNSRGlobal X - Internet of Things ETF$193M in assets5.93%
- IHIiShares US Medical Devices ETF$4.0B in assets3.92%
- MIGOMIG Core ETF$695M in assets3.10%
- TMFGMotley Fool Global Opportunities ETF$333M in assets2.74%
Largest holders first, then the funds most concentrated in DXCM.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold DexCom, Inc., and how their positions are changing. At a $30.44B market value, institutional positions materially move DexCom, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by DexCom, Inc. executives and directors. Shares of DexCom, Inc. have traded between $54.11 and $93.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming DexCom, Inc.. DexCom, Inc. is a $30.44B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming DexCom, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for DexCom, Inc.. Coverage tracks DexCom, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of DexCom, Inc.